Display options
Cite
Poluektov YO, Kim A, Sadegh-Nasseri S. HLA-DO and Its Role in MHC Class II Antigen Presentation. Front Immunol. 2013;4:260doi: 10.3389/fimmu.2013.00260.
Poluektov, Y. O., Kim, A., & Sadegh-Nasseri, S. (2013). HLA-DO and Its Role in MHC Class II Antigen Presentation. Frontiers in immunology, 4260. https://doi.org/10.3389/fimmu.2013.00260
Poluektov, Yuri O, et al. "HLA-DO and Its Role in MHC Class II Antigen Presentation." Frontiers in immunology vol. 4 (2013): 260. doi: https://doi.org/10.3389/fimmu.2013.00260
Poluektov YO, Kim A, Sadegh-Nasseri S. HLA-DO and Its Role in MHC Class II Antigen Presentation. Front Immunol. 2013 Aug 29;4:260. doi: 10.3389/fimmu.2013.00260. eCollection 2013. PMID: 24009612; PMCID: PMC3756479.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2013 Aug 29;4:260. doi: 10.3389/fimmu.2013.00260. eCollection 2013.

HLA-DO and Its Role in MHC Class II Antigen Presentation.

Frontiers in immunology

Yuri O Poluektov, Aeryon Kim, Scheherazade Sadegh-Nasseri

Affiliations

  1. Graduate Program in Immunology, Johns Hopkins University , Baltimore, MD , USA.

PMID: 24009612 PMCID: PMC3756479 DOI: 10.3389/fimmu.2013.00260

Abstract

Helper T cells are stimulated to fight infections or diseases upon recognition of peptides from antigens that are processed and presented by the proteins of Major Histocompatibility Complex (MHC) Class II molecules. Degradation of a full protein into small peptide fragments is a lengthy process consisting of many steps and chaperones. Malfunctions during any step of antigen processing could lead to the development of self-reactive T cells or defective immune response to pathogens. Although much has been accomplished regarding how antigens are processed and presented to T cells, many questions still remain unanswered, preventing the design of therapeutics for direct intervention with antigen processing. Here, we review published work on the discovery and function of a MHC class II molecular chaperone, HLA-DO, in human, and its mouse analog H2-O, herein called DO. While DO was originally discovered decades ago, elucidating its function has proven challenging. DO was discovered in association with another chaperone HLA-DM (DM) but unlike DM, its distribution is more tissue specific, and its function more subtle.

Keywords: HLA-DM; HLA-DO; HLA-DR antigens; MHC class II antigen processing; models for HLA-DO function

References

  1. J Exp Med. 2000 Dec 18;192(12):1697-706 - PubMed
  2. J Immunol. 2006 Mar 15;176(6):3548-56 - PubMed
  3. Immunol Rev. 2005 Oct;207:279-92 - PubMed
  4. Immunology. 2000 Feb;99(2):249-56 - PubMed
  5. J Hered. 2004 Jul-Aug;95(4):338-45 - PubMed
  6. J Immunol. 2009 Feb 15;182(4):1868-76 - PubMed
  7. Immunity. 2003 Aug;19(2):183-92 - PubMed
  8. Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11276-81 - PubMed
  9. Tissue Antigens. 2005 Mar;65(3):283-6 - PubMed
  10. Mol Immunol. 2009 Sep;46(15):3157-62 - PubMed
  11. J Biol Chem. 2000 Jan 21;275(3):2165-73 - PubMed
  12. J Immunol. 2008 Sep 1;181(5):3221-31 - PubMed
  13. Cell. 1996 Feb 23;84(4):531-41 - PubMed
  14. Nature. 1977 Jan 20;265(5591):248-51 - PubMed
  15. J Immunol. 2001 Apr 15;166(8):5087-98 - PubMed
  16. Cell. 1996 Feb 23;84(4):543-50 - PubMed
  17. Nature. 1994 Mar 17;368(6468):215-21 - PubMed
  18. Nat Rev Immunol. 2011 Nov 11;11(12):823-36 - PubMed
  19. Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16607-12 - PubMed
  20. Genes Immun. 2010 Jan;11(1):94-7 - PubMed
  21. J Immunol. 2013 Jan 1;190(1):126-37 - PubMed
  22. J Immunol. 2006 Mar 15;176(6):3536-47 - PubMed
  23. J Exp Med. 2002 Apr 15;195(8):1053-62 - PubMed
  24. PLoS Biol. 2013;11(5):e1001566 - PubMed
  25. J Immunol. 2003 Sep 1;171(5):2331-7 - PubMed
  26. Immunol Cell Biol. 2011 Nov;89(8):870-81 - PubMed
  27. Science. 1997 Oct 3;278(5335):106-9 - PubMed
  28. PLoS One. 2013 Aug 08;8(8):e71228 - PubMed
  29. EMBO J. 1996 Sep 16;15(18):4817-24 - PubMed
  30. Int Immunol. 1997 Mar;9(3):355-64 - PubMed
  31. J Immunol. 2004 Apr 1;172(7):4142-50 - PubMed
  32. Semin Arthritis Rheum. 2010 Apr;39(5):347-55 - PubMed
  33. Immunity. 1998 Sep;9(3):385-93 - PubMed
  34. Science. 1996 Mar 1;271(5253):1278-81 - PubMed
  35. Immunity. 1998 Sep;9(3):377-83 - PubMed
  36. Cell. 2012 Dec 21;151(7):1557-68 - PubMed
  37. Curr Biol. 1997 Dec 1;7(12):950-7 - PubMed
  38. Immunity. 1995 Nov;3(5):561-72 - PubMed
  39. Front Biosci (Schol Ed). 2012 Jun 01;4:1325-32 - PubMed
  40. Immunity. 1998 Feb;8(2):233-43 - PubMed
  41. J Biol Chem. 1985 Nov 15;260(26):14111-9 - PubMed
  42. Nat Struct Mol Biol. 2013 Jan;20(1):90-8 - PubMed
  43. J Immunol. 2012 Oct 15;189(8):3983-94 - PubMed
  44. Science. 1994 Dec 2;266(5190):1569-73 - PubMed
  45. J Immunol. 2007 Feb 1;178(3):1488-97 - PubMed
  46. Trends Immunol. 2013 Oct;34(10):495-501 - PubMed
  47. Nat Struct Mol Biol. 2013 Jan;20(1):7-10 - PubMed
  48. J Immunol. 2011 Oct 15;187(8):4151-60 - PubMed
  49. Nature. 1991 Jun 6;351(6326):485-8 - PubMed
  50. EMBO J. 1998 Jun 1;17(11):2971-81 - PubMed
  51. Immunology. 1990 May;70(1):66-74 - PubMed
  52. Immunol Res. 2010 Jul;47(1-3):56-64 - PubMed
  53. Proc Natl Acad Sci U S A. 2005 May 3;102(18):6443-8 - PubMed
  54. Eur J Immunol. 2000 Oct;30(10):2871-80 - PubMed
  55. Immunogenetics. 2003 Sep;55(6):402-11 - PubMed
  56. J Immunol. 1999 Mar 15;162(6):3463-70 - PubMed
  57. J Clin Invest. 2010 Apr;120(4):1324-36 - PubMed
  58. Nat Med. 2010 Nov;16(11):1333-40 - PubMed

Publication Types

Grant support